Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma

Soo Jin Bae, Christine Y. Kang, Ki Woong Sung, Hee Won Chueh, Meong Hi Son, Soo Hyun Lee, Keon Hee Yoo, Hong Hoe KooJournal of Korean Medical Science 2012 · DOI

Abstract

Tandem high-dose chemotherapy followed by autologous stem cell transplantation (HDCT/autoSCT) is a standard treatment for high-risk neuroblastoma but necessitates frequent red blood cell (RBC) transfusions, leading to iron overload. This study investigated serum ferritin levels and their impact on organ function in 49 pediatric patients. Results showed that nearly half (47.7%) of patients maintained ferritin levels above 1,000 ng/mL one year post-transplant. High iron levels were significantly associated with impaired renal function. The number of CD34+ cells transplanted was identified as the primary independent factor for sustained iron overload, suggesting that maximizing stem cell dose can mitigate long-term iron-related complications.

Introduction

High-risk neuroblastoma remains a significant challenge in pediatric oncology. The adoption of tandem HDCT/autoSCT has improved survival rates but introduces a heavy burden of RBC transfusions during the prolonged periods of cytopenia between transplants. While the acute risks of iron overload are well-documented, the long-term persistence of iron and its effects on organ function in survivors who no longer require transfusions are less understood. This study aims to characterize the trajectory of iron levels post-transplant and identify clinical predictors of sustained overload.

Methods

A retrospective analysis was performed on 49 children with high-risk neuroblastoma treated at Samsung Medical Center (2006–2010). Serum ferritin was measured at multiple time points: before the first transplant (T1), before the second (T2), and at intervals up to 36 months post-transplant. Organ function (cardiac, pulmonary, renal, endocrine, and auditory) was assessed at the one-year mark. Multivariate linear regression was used to determine independent factors associated with ferritin levels at one year.

Key Results

The study found that serum ferritin levels typically peak one month after the second transplant (median 2,297 ng/mL) before beginning a gradual decline. Despite this decrease, iron overload remains a persistent issue for many survivors.

Serum ferritin trends and correlations during post-SCT follow-up. (A) Levels peak at 1 month and decrease. (B) 47.7% of patients remain above 1,000 ng/mL at 1 year. (C) Transfusion volume correlates with 1-year ferritin levels.

Persistent Iron Burden and Organ Impact

At the one-year follow-up, 47.7% of patients still had ferritin levels exceeding 1,000 ng/mL. This sustained iron burden was linked to signs of organ stress:

  • Renal Function: Patients with ferritin > 1,000 ng/mL had significantly higher serum creatinine (0.62 vs 0.47 mg/dL, $P = 0.007$) and lower creatinine clearance compared to those with lower iron levels.
  • Liver Function: Higher Alanine Aminotransferase (ALT) levels were also observed in the high-iron group ($P = 0.011$).

Predictors of Overload

A strong positive correlation ($r = 0.735, P < 0.001$) was found between the total volume of RBCs transfused and ferritin levels at one year. Crucially, multivariate analysis revealed that the number of CD34+ cells transplanted was the only independent factor associated with ferritin levels at the one-year mark ($P = 0.019$). A higher stem cell dose facilitates faster engraftment, thereby reducing the duration of cytopenia and the subsequent need for RBC transfusions.

Discussion and Conclusion

These findings highlight that iron overload is a significant "late effect" in tandem transplant survivors. The correlation with elevated creatinine suggests that the kidneys may be particularly sensitive to iron-mediated damage in this population.

The study underscores the importance of stem cell collection. By maximizing the CD34+ cell dose, clinicians can accelerate hematopoietic recovery and minimize the cumulative iron burden. While iron chelation therapy is a potential intervention, its known nephrotoxicity necessitates caution, especially given the existing renal stress observed in patients with high iron levels. Future research using more direct measures of tissue iron, such as T2* MRI, is recommended to further refine management strategies for these survivors.

Summary updated

Abstract

Multiple RBC transfusions inevitably lead to a state of iron overload before and after high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT). Nonetheless, iron status during post-SCT follow-up remains unknown. Therefore, we investigated post-SCT ferritin levels, factors contributing to its sustained levels, and organ functions affected by iron overload in 49 children with high-risk neuroblastoma who underwent tandem HDCT/autoSCT. Although serum ferritin levels gradually decreased during post-SCT follow-up, 47.7% of the patients maintained ferritin levels above 1,000 ng/mL at 1 yr after the second HDCT/autoSCT. These patients had higher serum creatinine (0.62 vs 0.47 mg/mL, P = 0.007) than their counterparts (< 1,000 ng/mL). Post-SCT transfusion amount corresponded to increased ferritin levels at 1 yr after the second HDCT/autoSCT (P < 0.001). A lower CD34(+) cell count was associated with a greater need of RBC transfusion, which in turn led to a higher serum ferritin level at 1 yr after HDCT/autoSCT. The number of CD34(+) cells transplanted was an independent factor for ferritin levels at 1 yr after the second HDCT/autoSCT (P = 0.019). Consequently, CD34(+) cells should be transplanted as many as possible to prevent the sustained iron overload after tandem HDCT/autoSCT and consequent adverse effects.
BibTeX
@article{bae2012iron,
  author = {Soo Jin Bae and Christine Y. Kang and Ki Woong Sung and Hee Won Chueh and Meong Hi Son and Soo Hyun Lee and Keon Hee Yoo and Hong Hoe Koo},
  title = {{Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma}},
  journal = {Journal of Korean Medical Science},
  year = {2012},
  doi = {10.3346/jkms.2012.27.4.363},
}
Figure